AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval
AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval Simply Wall Street
Covered in this story
What has happened since
- AbbVie is up 2.3% since this was published, 4 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Guggenheim: $244 → $288 by Aug 2027 · Buy via GuruFocus
- Canaccord Genuity: $245 → $290 by Aug 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Also covered by 1 other outlet
Dalsna Finance is currently tracking 49 stories mentioning AbbVie, the earliest published 8 Jun 2026.
Summary aggregated from Simply Wall Street's public RSS feed. The full reporting belongs to Simply Wall Street — please read it on their site.